Dr. Oz Says The MMR Vaccine Is Not 'Lethal' as Trump Administration Faces Questions Over Vaccine Policy
Key takeaways
- Oz’s statement counters Trump’s claim that MMR is lethal, but the new policy could still shift demand toward separate shots, impacting vaccine manufacturers.
- 92.4% of U.S. kindergartners received the MMR vaccine during the 2025-26 school year
- The executive order narrowed federal recommendations to 11 core vaccines
- Merck’s M-M-R II and ProQuad, Sanofi’s Vaxelis, and GSK’s Priorix are the main products potentially affected
What happened
Centers for Medicare & Medicaid Services Administrator Mehmet Oz defended the Trump administration’s push for greater parental choice in childhood vaccines, specifically denying that the measles, mumps and rubella vaccine is "lethal." Oz appeared on CBS’s "Face the Nation" and clarified that the MMR vaccine is not lethal, while supporting the president’s call for flexibility in vaccine schedules. Trump’s executive order last month narrowed federal recommendations to 11 core vaccines and opened…
Why it matters
The debate over MMR safety and scheduling could influence public confidence in vaccines and affect demand for the combined MMR product. A shift toward separate shots may reduce sales for Merck’s M-M-R II and ProQuad, Sanofi’s Vaxelis, and GSK’s Priorix, while increasing demand for individual component vaccines. The…
Short-term and longer-term
Short-term. Short‑term traders should watch for any immediate impact on Merck, Sanofi, and stock prices as the market digests the potential shift toward separate MMR shots.
Longer-term. Over the next few months, investors should assess how the policy change may alter the competitive dynamics among the top MMR manufacturers.